Repligen Corp. insider Jason K. Garland reported changes in beneficial ownership of the company’s common stock in a Form 4 filed on July 17, 2026, covering transactions dated July 16, 2026. The filing indicates that Garland sold shares of Repligen common stock. The reported sales were made under a Rule 10b5-1 trading plan that Garland adopted on December 8, 2025. Such plans allow insiders to schedule future trades in advance, typically to reduce concerns that transactions are being made on the basis of material nonpublic information. The document identifies the security involved as Repligen common stock and notes that the ownership change occurred on July 16, 2026. However, the text provided does not include the transaction table that would normally show the specific number of shares sold, sale prices, transaction code, or Garland’s remaining beneficial ownership after the transactions. The Form 4 was signed on Garland’s behalf by Jennifer Carmichael, attorney-in-fact, on July 17, 2026. The key corporate-insider action reported is therefore an insider sale of Repligen common stock by Garland pursuant to a prearranged 10b5-1 trading plan.